Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Positions Curium as leading manufacturer of Lu-177 isotope
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Subscribe To Our Newsletter & Stay Updated
